CULLINAN THERAPEUTICS, INC. (CGEM) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 171.47M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 32.84M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -221.81M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.47M | (m) | $32.84M | $-221.81M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $188.07M | (m) | $34.28M | $-240.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $187.40M | (m) | $36.04M | $-241.65M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $184.95M | (m) | $38.36M | $-241.44M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $178.49M | (m) | $38.33M | $-234.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $153.72M | (m) | $38.97M | $-208.93M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $142.90M | (m) | $37.82M | $-196.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $137.26M | (m) | $35.71M | $-187.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $135.57M | (m) | $34.02M | $-183.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $126.71M | (m) | $31.41M | $-171.32M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $148.16M | (m) | $30.44M | $-191.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $134.63M | (m) | $30.43M | $-178.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $120.49M | (m) | $27.96M | $-162.74M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $119.51M | (m) | $28.65M | $114.55M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $91.95M | $0.00 | $27.96M | $144.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $91.50M | $0.00 | $32.59M | $142.91M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $84.50M | $0.00 | $31.88M | $154.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $69.87M | $0.00 | $27.43M | $-101.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $57.75M | $18.94M | $24.38M | $-67.95M | (m) | 304.87% | 128.68% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $43.21M | $0.00 | $14.91M | $-60.34M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |